Graves Disease

Obtain serum TSH with free T4 and free or total T3. Sensitive TSH is the most sensitive outpatient screening test for thyroid hormone excess. Suppressed TSH with elevated free T4 and/or T3 indicates overt thyrotoxicosis; the biochemical pattern alone does not distinguish Graves disease from autonomous nodules, thyroiditis, iodine-associated disease, or exogenous thyroid hormone use. ScienceDirect+1ScienceDirectAmerican Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and HypothyroidismccjmCleveland Clinic Journal of Medicine Approach to a low TSH level: Patience is a virtue

Do not label a patient with low TSH, normal free T4, and elevated T3 as having subclinical hyperthyroidism. Subclinical hyperthyroidism requires both free T4 and free T3 to be normal; isolated T3 elevation with suppressed TSH should prompt evaluation for toxic nodular goiter or early Graves disease. ccjmccjmCleveland Clinic Journal of Medicine Approach to a low TSH level: Patience is a virtue

Use the medication, supplement, pregnancy, and exposure history to direct testing. Specifically identify thyroid hormone ingestion, amiodarone or other iodine exposure, and recent postpartum status, because these point toward etiologies that require different management than thyroid-stimulating autoimmunity. ScienceDirectScienceDirectAmerican Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism

Order TRAb or TSI when Graves disease is suspected. TSH-receptor antibodies confirm Graves disease, and serial antibody measurements over months to years can help assess response to treatment. Thyroid scintigraphy, TRAb, and thyroid ultrasound are the three principal diagnostic tools used to establish the cause of thyrotoxicosis. Wiley+1WileyDiagnostic Options in Graves' or Non‐Graves' ThyrotoxicosisthyroidPediatric Thyroid Function Tests | American Thyroid Association

Use iodine-123 uptake and scan when antibody testing is unavailable, negative despite persistent clinical suspicion, or when a nodular gland or competing etiologies make the diagnosis uncertain. Diffuse uptake supports Graves disease. High uptake with focal or nodular patterns supports toxic adenoma or toxic multinodular goiter; low uptake redirects evaluation toward thyroiditis, ectopic thyroid hormone production, exogenous thyroid hormone, or iodine-related dysfunction. acpjournals+2acpjournalsHyperthyroidismccjmCleveland Clinic Journal of Medicine Approach to a low TSH level: Patience is a virtuethyroidPediatric Thyroid Function Tests | American Thyroid Association

Physical examination remains a useful discriminator but should not substitute for biochemical or imaging confirmation when treatment will be definitive. Ophthalmopathy and positive TRAb favor Graves disease, whereas toxic nodular goiter is generally TRAb-negative and lacks ophthalmopathy. ccjmccjmCleveland Clinic Journal of Medicine Approach to a low TSH level: Patience is a virtue

Use an antithyroid drug, radioactive iodine (RAI), or thyroidectomy as the principal treatment pathway for confirmed Graves disease. Antithyroid drugs are commonly associated with relapse, while RAI has historically been described as a common U.S. treatment choice; thyroidectomy remains an established option. The choice should explicitly account for orbitopathy, reproductive status, likelihood of sustained medical remission, gland anatomy, and preference for thyroid preservation versus definitive treatment. ScienceDirect+1ScienceDirectAmerican Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and HypothyroidismWileyBritish Thyroid Association Survey of Graves' Disease ...

Methimazole is the usual antithyroid agent in nonpregnant patients, but dose matters. Methimazole-associated agranulocytosis was more frequent with an initial 30 mg daily dose than with 15 mg daily, supporting use of the lowest effective starting dose rather than routine high-dose treatment. NatureNatureAntithyroid therapy—best choice of drug and dose

Long-term antithyroid therapy is a reasonable alternative to surgery or RAI for patients with persistent TRAb elevation who prefer medical management. Treatment beyond 24 months has been associated with higher remission rates than the traditional approximately 18-month course in contemporary reviews, although definitive therapy remains appropriate when medical therapy is ineffective, not tolerated, or inconsistent with patient goals. ScienceDirect+1ScienceDirectThe evolving therapeutic landscape of Graves’ disease in adults: present and futureScienceDirectManagement Aspects of Medical Therapy in Graves Disease

If selecting RAI, counsel that biochemical and clinical follow-up is required after treatment. In one cohort, assessment occurred at 1, 3, 6, and 12 months after a single treatment; higher maximal iodine uptake or longer effective half-life was associated with a greater likelihood of one-time cure, whereas older age and positive TRAb or thyroglobulin antibodies were associated with lower likelihood of one-time cure. Wolters KluwerWolters KluwerAnalysis of 131I therapy and correlation factors... : Nuclear Medicine Communications

Consider thyroidectomy when a definitive option is preferred or when RAI and prolonged drug therapy are unsuitable. Current guidance has generally recommended achieving euthyroidism before surgery to reduce perioperative risk, although evidence supporting a mandatory euthyroid state is described as inconclusive. cdn clinicaltrialscdn clinicaltrialsResearch plan/Protocol for HRO: Further use of biological ...

Screen every patient with Graves disease for eye symptoms and signs, then distinguish mild disease from moderate-to-severe active disease and sight-threatening disease. Contemporary EUGOGO and ATA/ETA documents broadly agree on classification, assessment, prevention, and management of mild, inactive, and sight-threatening Graves orbitopathy, but differ materially for moderate-to-severe active disease. ScienceDirectScienceDirectComparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy

For moderate-to-severe active orbitopathy, ATA/ETA consensus identifies teprotumumab as first-line treatment for virtually all phenotypes, particularly when exophthalmos predominates. The same consensus favors intravenous glucocorticoids when the primary goal is inactivation and resolution of inflammation; intravenous glucocorticoids plus orbital radiotherapy are among preferred approaches when inactivation and correction of eye dysmotility are the goals. ScienceDirectScienceDirectComparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy

EUGOGO instead identifies intravenous glucocorticoids, with or without mycophenolate, as first-line therapy for moderate-to-severe active disease. This is a genuine treatment-choice controversy; phenotype and therapeutic objective should drive the discussion rather than treating all active orbitopathy as a single entity. ScienceDirectScienceDirectComparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy

Avoid treating thyroid autonomy and orbitopathy as separate problems. RAI requires caution in patients with moderate-to-severe active orbitopathy, and future guidance may reconsider cautious RAI use only in conjunction with intravenous glucocorticoids, with or without orbital radiotherapy. ScienceDirectScienceDirectComparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy

Reassess antithyroid drug requirement frequently throughout pregnancy. Graves disease may improve during the second and third trimesters, and low doses or discontinuation of antithyroid drugs may be possible in the third trimester when maternal disease activity permits. JAMA+1JAMATreatment Guidelines for Patients With Hyperthyroidism and ...Wolters KluwerThyroid Disease in Pregnancy

Do not equate prior definitive therapy or maternal clinical quiescence with absence of fetal risk. Women with current Graves disease or a past Graves history can have fetal thyrotoxicosis because maternal TSH-receptor antibodies cross the placenta. Wolters KluwerWolters KluwerFetal Thyrotoxicosis due to Maternal TSH Receptor... : Hormone Research in Paediatrics

Use TRAb as both a diagnostic and longitudinal marker in Graves disease; in pregnancy, a current or prior Graves history should trigger consideration of fetal risk from transplacental antibodies even when the maternal thyroid is no longer hyperfunctioning. Wolters Kluwer+1Wolters KluwerFetal Thyrotoxicosis due to Maternal TSH Receptor... : Hormone Research in PaediatricsthyroidPediatric Thyroid Function Tests | American Thyroid Association